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Acetylcholinesterase inhibitor treatment alleviated
cognitive impairment caused by delayed
encephalopathy due to carbon monoxide
poisoning
Two case reports and a review of the literature
Kumi Yanagiha, MD, Kazuhiro Ishii, MD, PhD
∗
, Akira Tamaoka, MD, PhD
Abstract
Introduction:Delayed encephalopathy due to carbon monoxide (CO) poisoning can even occur in patients with mild symptoms of
acute CO poisoning. Some cases taking conventional hyperbaric oxygen (HBO) therapy or steroid-pulse therapy may be insufﬁcient,
and AchEI may be effective.
Patient Concerns and Diagnoses:We report two cases of delayed encephalopathy after acute CO poisoning involving two
women aged 69 (Case 1) and 60 years (Case 2) whose cognitive function improved with acetylcholinesterase inhibitor (AchEI)
treatment. Delayed encephalopathy occurred 25 and 35 days after acute CO poisoning in Case 1 and Case 2, respectively. Both
patients demonstrated cognitive impairment, apathy, and hypokinesia on admission.
Interventions and Outcomes: Although hyperbaric oxygen therapy did not yield any signiﬁcant improvements, cognitive
dysfunction improved substantially. This was evidenced by an improved Mini-Mental State Examination score ffom 9 to 28 points in
Case 1 and an improved Hasegawa’s dementia rating scale score from 4 to 25 points in Case 2 after administration of an AchEI.
In Case 1, we administered galantamine hydrobromide, which was related with improved white matter lesions initially detected on
brain magnetic resonance imaging. However, in Case 2 white matter lesions persisted despite AchEI treatment. AchEI treatment may
result in improved cognitive and frontal lobe function by increasing low acetylcholine concentrations in the hippocampus and frontal
lobe caused by decreased nicotinic acetylcholine receptor levels in delayed encephalopathy after CO poisoning.
Conclusion: Physicians should consider AchEIs for patients demonstrating delayed encephalopathy due to CO poisoning.
Abbreviations: AchEI = acetylcholinesterase inhibitor, CO = carbon monoxide, DWI = diffusion-weighted image, HBO =
hyperbaric oxygen, MMSE = Mini-Mental State Examination, MRI = magnetic resonance imaging, T2WI = T2-weighted image.
Keywords: acute carbon monoxide poisoning, acetylcholinesterase inhibitor, carbon monoxide delayed encephalopathy, case
report, donepezil hydrochloride, galantamine hydrobromide
1. Introduction
Neurological symptoms caused by carbonmonoxide (CO) can be
divided into immediate and delayed symptoms, with an
intervening asymptomatic period (lucid interval). Immediate
symptoms occur just after CO exposure, also known as acute CO
poisoning. Delayed symptoms can occur following a 2 to 4-week
lucid interval following clinical remission of acute CO poisoning.
Such delayed encephalopathy due to CO poisoning is associated
with frontal lobe dysfunction, including hypokinesia, cognitive
impairment, and psychiatric symptoms.[1,2] Delayed encephalop-
athy due to CO poisoning can even occur in patients with mild
symptoms of acute CO poisoning. This is possibly due to the
hypoxia of brain tissues, the increased oxidative stress, or
membranous lipid peroxide that results from mitochondrial
dysfunction, rather than direct anoxic damage. However, the
pathogenesis remains unclear.[1]
Hyperbaric oxygen (HBO) therapy and immune therapy are
administered for the treatment or prevention of delayed encepha-
lopathy after CO poisoning. However, a retrospective case study
reports ahalfpatient (23of46)ofdelayedencephalopathyafterCO
poisoning showed severe cognitive or physical sequelae in spite
of HBO treatment was provided.[3] Therefore, a useful therapy
is longed for this state. Recently, several studies have reported
cognitive impairment due to delayed encephalopathy that occurred
in patients with CO poisoning who demonstrated improvements
after treatment with an acetylcholinesterase inhibitor (AchEI).[4,5]
Here, we report 2 cases of delayed encephalopathy after acute CO
poisoning in which cognitive impairment and movement disorder
were dramatically improved following treatmentwith galantamine
hydrobromide and donepezil hydrochloride.
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2. Case report
2.1. Case 1
A 69-year-old woman was admitted to the hospital 12hours after
attempting suicide using burning artiﬁcial coal. Upon admission,
the patient was diagnosed with acute CO poisoning and treated
with normobaric oxygen therapy. She was discharged 4 days later
without any disturbance of consciousness or movement disor-
ders. Twenty-ﬁve days after the acute CO poisoning, she began to
experience amnesia, apathy, gait disturbance, and urinary
incontinence, which worsened within a few days.
The patient was admitted to our hospital 35 days after the CO
poisoning. On examination, she demonstrated an apathetic state
and decreasing spontaneous speech ability. However, she could
maintain a conversation and follow simple instructions. She had a
Mini-Mental State Examination (MMSE) score of 9/30 and a
Frontal Assessment Battery score of 3/18, which showed both
cognitive and frontal lobe dysfunction severely. She exhibited
hypokinesia, frozen gait, and a bilateral palmomental reﬂex.
Sensory disturbance and cerebellar dysfunction were not detected.
Hematological values, hepatic and renal function, clotting
times, thyroid function, ammonia level, vitamin B1 level, vitamin
B12 level, and tumor marker levels were all within the normal
range, and antinuclear autoantibodies were not detectable.
Examination of the cerebrospinal ﬂuid showed cells (all
monocytes: 6cells/mL), a slightly elevated protein level (52mg/
dL; normal: 10–40mg/dL), an elevated myelin basic protein level
(422pg/mL; normal: <102pg/mL), and an oligoclonal band.
Brain magnetic resonance imaging (MRI) showed high-intensity
lesions in the white matter of the frontal, temporal, and parietal
lobes on a T2-weighted image (T2WI) and a diffusion-weighted
image (DWI; Fig. 1A). Decreased cerebral blood ﬂow in the
frontal lobes was observed on 123I-IMP-single photon emission
computed tomography. On electroencephalography, 5 to 7Hz
slow waves were observed in the basic rhythm, but paroxysmal
discharges were not observed. Dopamine transporter scintigra-
phy demonstrated normal uptake in striatal areas, with a speciﬁc
binding ratio of 6.33 for the right side and 5.74 for the left side
(normal SBR range, mean±2SD: 5.25±1.34). Taken together,
the results of these examinations indicated delayed encephalopa-
thy due to CO poisoning.
The patient was administered vitamins E, B1, and B12 35 days
after acute CO poisoning. HBO therapy (2atm abs, 120minutes,
every other day) was administered 40 days after acute CO
poisoning and continued over 17 subsequent sessions. However,
the treatment resulted in only mild or transient therapeutic
effects. She was administered galantamine hydrobromide after an
agreement for adequate informed consent without steroid
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Figure 1. Brain MRI ﬁndings for case 1 at the onset (35 days after acute CO
poisoning) of delayed encephalopathy (A) and 1 year later (B). (A) Axial view DWI
showing bilateral, symmetrical high-intensity lesions in the white matter (upper).
The white matter lesions demonstrate symmetrical high-intensity lesions on
coronal FLAIR image (middle). Axial view T2WI showing a faint high-intensity
lesion mainly located in the white matter (lower). (B) One year later, the white
matter lesions previously observed disappeared completely. However, cerebral
atrophy was observed on MRI. CO=carbon monoxide, DWI=diffusion-
weighted image, FLAIR=ﬂuid-attenuated inversion recovery, MRI=magnetic
resonance imaging, T2WI=T2-weighted image.
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Figure 1. (Continued).
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therapy. Then, 69 days after acute COpoisoning, the patient took
galantamine hydrobromide at 8mg/day as initial dose, and 28
days after the dose was increased to 16mg/day as described in the
instructions. She did not receive any other medicine except for
galantamine hydrobromide after this point in time. Five days
later, the patient demonstrated improvement of attention as
recovery of spontaneous speech, and there were drastic improve-
ments in disorientation and gait disturbance. The improvement in
cognitive function 38 days after initiating galantamine hydro-
bromide treatment was remarkable, with an MMSE score of 28/
30 and a Frontal Assessment Battery score of 18/18. 123I-IMP-
single photon emission computed tomography performed 38
days after the administration of galantamine hydrobromide
showed increased cerebral blood ﬂow throughout, especially in
the frontal lobes. Thirty-nine days after initiating treatment with
galantamine hydrobromide, and 74 days from the day of
admission, the patient was discharged. At this point, she could
perform activities of daily living almost independently. Brain
MRI performed 1 year later showed disappearance of high-
intensity areas on a DWI and only mild evidence of high-intensity
lesions in the diffuse white matter on a T2WI (Fig. 1B).
Symptomatic improvement and the related improvements seen on
brain imaging have continued for the past 3 years with
galantamine hydrobromide medication.
2.2. Case 2
A 60-year-old woman was admitted to a nearby hospital for
acute CO poisoning due to attempted suicide using the exhaust
gas of a car. She was discharged about a week later without
any persisting symptoms. However, 35 days after acute CO
poisoning, she began to experience hypokinesia, amnesia, and
incommunicative behavior.
Subsequently, 43 days after acute CO poisoning, she visited a
local hospital. On admission, there were no abnormal physical
ﬁndings, but the patient demonstrated apathy, bradyphrenia,
hypokinesia, paratonia in the upper extremities, forced gripping,
and gait disturbance. She showed cognitive, especially memory
dysfunction as Hasegawa dementia rating scale (HDS-R) score of
10/30. Blood tests including those for vitamins, tumor markers,
autoantibodies, and hormone functions all yielded normal
results. Brain MRI showed high-intensity areas in the cerebral
white matter on a T2WI and a DWI (Fig. 2).
FiftydaysafteracuteCOpoisoning (and15daysafter thedelayed
encephalopathy) she was diagnosed with delayed encephalopathy
due toCOpoisoningandwas immediately instructed toundergo10
sessions of HBO treatment (2atm abs, 120minutes, every other
day) without steroid therapy. Before and after HBO therapy, the
HDS-R score was maintained at 4/30, indicating no improvement.
Seventy four days after acute CO poisoning, the patient started to
takedonepezil hydrochloride at 3mg/day under adequate informed
consent, and thedosewas increased to5mg in34days fromstarting
donepezil hydrochloride. Sixmonths after acuteCOpoisoning, her
disorientation, apathy, and hypokinesia improved at outpatient
consultation, and she could go shopping by herself on a bicycle and
her HDS-R score improved to 25/30. Symptomatic improvement
and related improvements on brain imaging have continued over
the past 10 years without any adverse events.
3. Discussion
We have described 2 cases of delayed encephalopathy due to CO
poisoning that manifested as cognitive impairment, apathy,
hypokinesia, and gait disturbance, and that occurred approxi-
mately 4 weeks after clinical remission of acute CO poisoning.
The patients were diagnosed with delayed encephalopathy due to
CO poisoning based on the presence of high-intensity signals in
brain white matter observed on T2WI, ﬂuid-attenuated inversion
recovery, and DWI.
Delayed encephalopathy due to CO poisoning typically
presents with slow and delayed neuronal cell death and
demyelination after CO exposure. The mechanism of delayed
encephalopathy due to CO poisoning is assumed to be related to
oxygenation deﬁciency caused by carboxyhemoglobin and CO
accumulation in brain tissue. This leads to lipid peroxidation via
peroxidase activation and mitochondrial cytochrome c oxidase
disorder, which slowly reduce mitochondrial energy production
in neurons and oligodendrocytes.[1]
Little is known about cognitive impairment caused by delayed
encephalopathy due to CO poisoning. However, studies of
animals exposed to CO have reported demyelination and axonal
degeneration in the hippocampus due to the degradation of
myelin basic protein.[6] The latter results from decreasing neurons
and nicotinic acetylcholine receptor levels,[7] and the reduction of
acetylcholine levels in the frontal lobe.[8] A previous study also
reported that an immunologic mechanismmay be associatedwith
Figure 2. Brain MRI ﬁndings for case 2, 6 months after the onset. Unlike in
case 1, the bilateral, high-intensity lesions in the cerebral white matter could still
be detected on FLAIR image and the T2WI, but not on DWI. Additional
characteristics of acute carbon monoxide poisoning, such as necrosis in the
globus pallidi, was observed on the T2WI. DWI=diffusion-weighted image,
FLAIR=ﬂuid-attenuated inversion recovery, MRI=magnetic resonance ima-
ging, T2WI=T2-weighted image.
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cognitive dysfunction caused by delayed encephalopathy due to
CO poisoning.[9]
Delayed encephalopathy due to CO poisoning is traditionally
treated with HBO and steroid therapy, but the effects are often
not adequate.[1] In our 2 cases, HBO treatment was the only
traditional therapy we administered. Recently, a few studies have
reported favorable outcomes for AchEI treatment for delayed
encephalopathy due to CO poisoning.[4,5] Therefore, we
administered AchEI, which resulted in some improvement in
the delayed encephalopathy. As shown in Table 1, the MMSE
score in case 1 improved from 9 to 28 and HDS-R score in case 2
improved from 4 to 25 following AchEI treatment.
The precise mechanism underlying improvements in clinical
symptoms of delayed encephalopathy due to CO poisoning
brought about by AchEI is poorly understood. However, it is
thought that AchEI strengthens hippocampal acetylcholinergic
neuron function such that delayed neuronal death by CO
reactivation is prevented.[7] In addition, AchEIs demonstrate
pleiotropic effects. They are known to act as neuroprotective
agents by exerting antiapoptotic effects in cortical and
hippocampal neurons, elevating Bcl-2 expression, stimulating
nicotinic acetylcholine receptors, activating the PI-3K/Akt
pathway, and suppressing glycogen synthase kinase-3.[4,5,10]
The dysfunction of nicotinic acetylcholinergic neurons in the
hippocampus was conﬁrmed using an animal model of delayed
encephalopathy due to CO poisoning.[7] Therefore, galantamine
hydrobromide, which demonstrates allosteric[11] and protec-
tive[12] effects against nicotinic acetylcholinergic neuronal
damage, has greater advantages than donepezil hydrochloride
in terms of treating delayed encephalopathy.
In case 1, where galantamine hydrobromide was administered,
most of the white matter lesions disappeared, and only mild
cortical atrophy was observed on brain MRI. These ﬁndings
indicate that galantamine hydrobromide affects not only neurons
but also oligodendrocytes.
Of course, there are some limitations to consider in the
presentation of these cases. For example, the efﬁcacy of AchEI
alone cannot be commented on as there may have been delayed
effects of HBO therapy. Furthermore, the CO exposure
conditions differed between the 2 cases, meaning we cannot
draw direct comparisons. Indeed, additional data for cases of
delayed encephalopathy due to CO poisoning need to be
collected. In addition, future studies should compare the effects
of galantamine hydrobromide and donepezil hydrochloride in
large double-blind randomized controlled studies.
4. Conclusion
We reported 2 cases of improved cognitive and frontal lobe
function following treatment of delayed encephalopathy due to
CO poisoning with AchEIs (galantamine hydrobromide and
donepezil hydrochloride). The pathogenesis of delayed encepha-
lopathy due to CO poisoning is associated with the loss and
dysfunction of hippocampal and frontal cortical neurons.
Therefore, AchEIs are effective against hippocampal symptoms
(cognitive dysfunction) and frontal lobe symptoms (apathy,
hypokinesia, and gait disturbance). From the point of functional
mechanism like allosteric and protective effects against nicotinic
acetylcholinergic neuron, galantamine hydrobromide is predicted
demonstrating a superior effect on nicotinic acetylcholinergic
neurons compared with donepezil hydrochloride.
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Table 1
Case reports of successful treatment of delayed encephalopathy due to carbon monoxide poisoning using an AchEI.
Wang et al[4] Song et al[5] Case 1 Case 2
Age, year/sex 60/M 16/M 69/F 60/F
COHb level at admission 11.2% 17% NA NA
Consciousness disturbance Present Present Present Present
Treatment for CO poisoning HBO HBO NBO/HBO NBO/HBO
Onset of delayed symptoms, day 25 25 25 35
High-intensity regions on T2-MRI NA Cerebral white matter,
basal ganglion
Cerebral white matter White matter of the frontal
lobe, basal ganglion
Type of AchEI administered Donepezil, 10mg Donepezil, 5mg Galantamine, 16mg Donepezil, 5mg
Improvement in cognitive function MMSE 9→25 MMSE 8→26 MMSE 9→28 FAB 3→18 HDS-R 4→25
AchEI=acetylcholinesterase inhibitor, CO= carbon monoxide, COHb=carboxyhemoglobin, FAB= Frontal Assessment Battery, HBO=hyperbaric oxygen, HDS-R=Hasegawa dementia rating scale, MMSE=
Mini-Mental State Examination, MRI=magnetic resonance imaging, NA=not available, NBO=normobaric oxygen.
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